ES2667418T3 - Composiciones y métodos para el tratamiento de la enfermedad celíaca - Google Patents
Composiciones y métodos para el tratamiento de la enfermedad celíaca Download PDFInfo
- Publication number
- ES2667418T3 ES2667418T3 ES12748354.3T ES12748354T ES2667418T3 ES 2667418 T3 ES2667418 T3 ES 2667418T3 ES 12748354 T ES12748354 T ES 12748354T ES 2667418 T3 ES2667418 T3 ES 2667418T3
- Authority
- ES
- Spain
- Prior art keywords
- amino acid
- seq
- acid sequence
- wild
- kumamolysin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000015943 Coeliac disease Diseases 0.000 title description 8
- 238000000034 method Methods 0.000 title description 3
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 22
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 21
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 19
- 229920001184 polypeptide Polymers 0.000 abstract description 15
- 150000001413 amino acids Chemical class 0.000 abstract description 8
- 108091005804 Peptidases Proteins 0.000 description 14
- 239000004365 Protease Substances 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 235000019419 proteases Nutrition 0.000 description 9
- 108010068370 Glutens Proteins 0.000 description 8
- 235000021312 gluten Nutrition 0.000 description 8
- 108010038807 Oligopeptides Proteins 0.000 description 6
- 102000015636 Oligopeptides Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 108010061711 Gliadin Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 108010016626 Dipeptides Proteins 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 108010059378 Endopeptidases Proteins 0.000 description 2
- 102000005593 Endopeptidases Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108010049331 kumamolysin Proteins 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 241001442202 Alicyclobacillus sendaiensis Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- LCGISIDBXHGCDW-VKHMYHEASA-N L-glutamine amide Chemical compound NC(=O)[C@@H](N)CCC(N)=O LCGISIDBXHGCDW-VKHMYHEASA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 108091007735 digestive proteases Proteins 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161521899P | 2011-08-10 | 2011-08-10 | |
| US201161521899P | 2011-08-10 | ||
| PCT/US2012/050364 WO2013023151A2 (en) | 2011-08-10 | 2012-08-10 | Compositions and methods for treating celiac sprue disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2667418T3 true ES2667418T3 (es) | 2018-05-10 |
Family
ID=46690751
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12748354.3T Active ES2667418T3 (es) | 2011-08-10 | 2012-08-10 | Composiciones y métodos para el tratamiento de la enfermedad celíaca |
| ES18162586T Active ES2896489T3 (es) | 2011-08-10 | 2012-08-10 | Composiciones y procedimientos para el tratamiento de la enfermedad esprúe celíaco |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18162586T Active ES2896489T3 (es) | 2011-08-10 | 2012-08-10 | Composiciones y procedimientos para el tratamiento de la enfermedad esprúe celíaco |
Country Status (18)
| Country | Link |
|---|---|
| US (7) | US9289473B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP4023243A3 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6342802B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2882502A1 (cg-RX-API-DMAC7.html) |
| CY (1) | CY1120877T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2718434T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2667418T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20180687T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE037870T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT2718434T (cg-RX-API-DMAC7.html) |
| NO (1) | NO2718434T3 (cg-RX-API-DMAC7.html) |
| PL (2) | PL3400958T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2718434T (cg-RX-API-DMAC7.html) |
| RS (1) | RS57234B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI2718434T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT201800249T1 (cg-RX-API-DMAC7.html) |
| TR (1) | TR201806885T4 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013023151A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20180687T1 (hr) | 2011-08-10 | 2018-06-15 | University Of Washington Through Its Center For Commercialization | Kompozicije i metode za liječenje celijakije spru |
| CN119424620A (zh) | 2013-08-14 | 2025-02-14 | 华盛顿大学商业中心 | 用于治疗口炎性腹泻的组合物和方法 |
| EP3081942A1 (en) * | 2015-04-17 | 2016-10-19 | Roche Diagniostics GmbH | Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample |
| HK1245129A1 (zh) * | 2015-06-08 | 2018-08-24 | University Of Washington | 治疗腹腔疾病的组合物及方法 |
| MX2019007287A (es) | 2016-12-22 | 2019-09-27 | Ew Nutrition Gmbh | Variantes de proteasas estables. |
| WO2020087017A1 (en) * | 2018-10-26 | 2020-04-30 | The Regents Of The University Of California | Use of proteolytic enzymes to enhance protein bioavailability |
| US20240226248A9 (en) * | 2018-10-26 | 2024-07-11 | The Regents Of The University Of California | Methods and compositions for improving protein hydrolysis |
| EP4237554A1 (en) | 2020-10-30 | 2023-09-06 | University of Washington | Compositions and methods for treating celiac sprue disease |
| CN119136820A (zh) | 2022-01-26 | 2024-12-13 | 迪杰斯蒂维公司 | 稳定血液葡萄糖的方法和组合物 |
| WO2025068987A1 (en) | 2023-09-28 | 2025-04-03 | Takeda Pharmaceutical Company Limited | A method of producing a kumamolisin-as polypeptide |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2688229B1 (fr) | 1992-03-09 | 1995-06-23 | Ulice Soc | Procede de synthese enzymatique d'esters alkyliques de peptides, produits ainsi obtenus et utilisation desdits produits. |
| JP2002078489A (ja) * | 2000-09-04 | 2002-03-19 | Daiwa Kasei Kk | セリン残基が活性発現に関与する新規酸性プロテアーゼ |
| US7320788B2 (en) | 2002-02-14 | 2008-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for Celiac Sprue |
| US8143210B2 (en) | 2002-02-14 | 2012-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
| EP2409711B1 (en) | 2002-02-14 | 2018-11-21 | The Board of Trustees of the Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
| AU2003234634A1 (en) | 2002-05-14 | 2003-12-02 | Felix Hausch | Drug therapy for celiac sprue |
| US7265093B2 (en) | 2002-05-14 | 2007-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for Celiac Sprue |
| US7202216B2 (en) | 2002-05-14 | 2007-04-10 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for celiac sprue |
| US7462688B2 (en) | 2002-05-14 | 2008-12-09 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for diagnostic and therapeutic methods for celiac sprue |
| WO2004045392A2 (en) | 2002-11-20 | 2004-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic method for celiac sprue |
| US7579313B2 (en) | 2003-11-18 | 2009-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | Transglutaminase inhibitors and methods of use thereof |
| US7534426B2 (en) | 2004-04-26 | 2009-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Glutenase enzyme assays |
| US7628985B2 (en) | 2004-04-26 | 2009-12-08 | The Board Of Regents Of The Leland Stanford Junior University | Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis |
| US7563864B2 (en) | 2004-04-26 | 2009-07-21 | Celiac Sprue Research Foundation | Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten |
| EP1600141B1 (en) | 2004-05-24 | 2013-04-17 | 3M Deutschland GmbH | Collagenolytic active enzyme containing compositions for the treatment of dental caries |
| EP1726643A1 (en) * | 2005-05-27 | 2006-11-29 | Direvo Biotech AG | Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances |
| EP2321640B1 (en) | 2008-08-21 | 2016-11-30 | Immunogenics LLC | Formulation for oral administration of proteins |
| HRP20180687T1 (hr) | 2011-08-10 | 2018-06-15 | University Of Washington Through Its Center For Commercialization | Kompozicije i metode za liječenje celijakije spru |
| US20140356345A1 (en) | 2011-12-06 | 2014-12-04 | Fondazione Istituto Insubrico Di Ricerca Per La Vita | New Proteases Able to Hydrolyze Gluten Peptides and Proteins at Acidic PH, from the Actinomycete Actinoallomurus |
| CN119424620A (zh) | 2013-08-14 | 2025-02-14 | 华盛顿大学商业中心 | 用于治疗口炎性腹泻的组合物和方法 |
-
2012
- 2012-08-10 HR HRP20180687TT patent/HRP20180687T1/hr unknown
- 2012-08-10 JP JP2014525175A patent/JP6342802B2/ja active Active
- 2012-08-10 SI SI201231269T patent/SI2718434T1/en unknown
- 2012-08-10 EP EP21187810.3A patent/EP4023243A3/en active Pending
- 2012-08-10 US US14/131,601 patent/US9289473B2/en active Active
- 2012-08-10 ES ES12748354.3T patent/ES2667418T3/es active Active
- 2012-08-10 LT LTEP12748354.3T patent/LT2718434T/lt unknown
- 2012-08-10 PL PL18162586T patent/PL3400958T3/pl unknown
- 2012-08-10 PT PT127483543T patent/PT2718434T/pt unknown
- 2012-08-10 PL PL12748354T patent/PL2718434T3/pl unknown
- 2012-08-10 WO PCT/US2012/050364 patent/WO2013023151A2/en not_active Ceased
- 2012-08-10 EP EP12748354.3A patent/EP2718434B1/en active Active
- 2012-08-10 TR TR2018/06885T patent/TR201806885T4/tr unknown
- 2012-08-10 RS RS20180609A patent/RS57234B1/sr unknown
- 2012-08-10 SM SM20180249T patent/SMT201800249T1/it unknown
- 2012-08-10 DK DK12748354.3T patent/DK2718434T3/en active
- 2012-08-10 CA CA2882502A patent/CA2882502A1/en active Pending
- 2012-08-10 EP EP18162586.4A patent/EP3400958B1/en active Active
- 2012-08-10 ES ES18162586T patent/ES2896489T3/es active Active
- 2012-08-10 NO NO12748354A patent/NO2718434T3/no unknown
- 2012-08-10 HU HUE12748354A patent/HUE037870T2/hu unknown
-
2016
- 2016-01-26 US US15/006,341 patent/US9707280B2/en active Active
-
2017
- 2017-06-26 US US15/633,065 patent/US9925249B2/en active Active
- 2017-07-07 JP JP2017133615A patent/JP6502428B2/ja active Active
-
2018
- 2018-02-14 US US15/896,536 patent/US10149892B2/en active Active
- 2018-06-21 CY CY181100648T patent/CY1120877T1/el unknown
- 2018-11-28 US US16/203,109 patent/US10874720B2/en active Active
-
2019
- 2019-03-20 JP JP2019052599A patent/JP2019162107A/ja active Pending
-
2020
- 2020-12-07 US US17/114,294 patent/US20210085761A1/en not_active Abandoned
-
2021
- 2021-03-23 JP JP2021048356A patent/JP2021094031A/ja active Pending
-
2023
- 2023-11-20 US US18/513,879 patent/US20240207376A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002401A patent/JP2024028452A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2667418T3 (es) | Composiciones y métodos para el tratamiento de la enfermedad celíaca | |
| Oliveira et al. | The chemistry of snake venom and its medicinal potential | |
| ES2746173T3 (es) | Uso de endoproteasas específicas para prolina para hidrolizar péptidos y proteínas | |
| ES2437569T3 (es) | Prolil endopeptidasa (PEP) y glutamina endoproteasa para el tratamiento de la celiaquía | |
| Lin et al. | Antihypertensive properties of tilapia (Oreochromis spp.) frame and skin enzymatic protein hydrolysates | |
| US20240158774A1 (en) | Compositions and Methods for Treating Celiac Sprue Disease | |
| CN114805483B (zh) | 五种来源于红小豆蛋白的胰脂肪酶抑制剂及其应用 | |
| US20090304754A1 (en) | Pegylated glutenase polypeptides | |
| WO2012174127A1 (en) | Proteases for degrading gluten | |
| JP2021073236A (ja) | グルテン不耐症及びそれから生じる障害を治療するための組成物及び方法 | |
| CN114634552B (zh) | 一种抗肥胖十三肽及其应用 | |
| US20130045195A1 (en) | Proteases for Degrading Gluten | |
| Tang et al. | Discovery of two novel ACE inhibitory peptides from soybeans: Stability, molecular interactions, and in vivo antihypertensive effects | |
| Xu et al. | Isolation and identification of thrombin-inhibiting peptides derived from soybean protein | |
| Gu et al. | Identification of a novel post-digestion angiotensin I-converting enzyme inhibitory peptide from silver Prussian carp (Carassius auratus gibelio) roe | |
| US20150197738A1 (en) | Acid Stable Prolyl Endopeptidases for Degrading Gluten | |
| Razwi et al. | Biochemical analysis of granzyme H and elucidation of its structurally important residues involved in substrate and inhibitor binding | |
| KR20150145067A (ko) | 단백질 분해 효소를 이용한 알레르기 항원성이 저감화된 대두의 제조 방법 | |
| JP2010047508A (ja) | プロテアーゼ阻害剤及びそれを含む医薬 | |
| Zamyatnin Jr et al. | Assessment of Triticain-α glutenase and collagenase activities for use in enzymatic therapy assays |